My watch list
my.chemeurope.com  
Login  

02-25-2005: Chiron Corporation announced the appointment of Jack Goldstein, 57, to the position of president and chief operating officer. Dr. Goldstein has served in this capacity on an interim basis since November 2004 and previously served as president of Chiron Blood Testing.

As president and COO, Dr. Goldstein will continue to oversee Chiron's day-to-day business operations and report to CEO Howard Pien. Mr. Pien will continue to set the direction of the organization, leading the executive committee in establishing strategy and realizing objectives, as well as guide Chiron's remediation efforts for the company's Liverpool manufacturing facility, which produces FLUVIRIN(R) influenza virus vaccine.

Chiron also announced the appointments of Gene Walther, 50, as president of Chiron Blood Testing, following his appointment as acting president of Chiron Blood Testing in November, and Daniel Soland, 46, as president of Chiron Vaccines. Mr. Walther was previously vice president for Chiron Blood Testing commercial operations, Americas. Mr. Soland, who brings more than two decades of pharmaceuticals and vaccines experience, succeeds John Lambert, who has resigned his position with Chiron. Both Mr. Walther and Mr. Soland will report to Dr. Goldstein.

Watchlist

This is where you can add this news to your personal favourites

Facts, background information, dossiers
More about Chiron
  • News

    Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing

    Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was anno ... more

    Chiron Delivers FLUVIRIN(R) Influenza Virus Vaccine to U.S. Customer

    Chiron Corporation announced that it has initiated the first delivery and release of FLUVIRIN(R) influenza virus vaccine to customers in the United States for the 2005-2006 influenza season. The company expects to continue to deliver shipments of FLUVIRIN vaccine throughout October and Nove ... more

    Chiron Responds to Novartis Offer

    Chiron Corporation issued the following statement from Chiron's independent board directors in response to the offer from Novartis AG on September 1, 2005, to acquire the approximately 58% of Chiron shares that Novartis does not already own for $40 per Chiron share in cash: "Over the 10 ye ... more

  • Companies

    Chiron AS

    Chiron is a 20 year old company with main office in the lovely city of Trondheim in the northern country of Norway. Our staff is comprised of 17 talented people with backgrounds in Chemistry, Biochemistry and Economics. Gruppebilde-ChironSince 1983 we have supplied reference standards of ... more

Most read news
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE